Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.65% $0.511
America/New_York / 30 okt 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 19.42 mill |
EPS: | -20.70 |
P/E: | -0.0247 |
Earnings Date: | Oct 25, 2023 |
SharesOutstanding: | 37.98 mill |
Avg Daily Volume: | 0.437 mill |
RATING 2023-10-30 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | ||||
Ebit | n/a | |||||
Asset | ||||||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0247 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0247 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 7.63 - 7.71 ( +/- 0.48%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-20 | Luo Ying | Buy | 3 350 897 | Stock Option (Right to Buy) |
2023-10-30 | Luo Ying | Buy | 2 840 376 | Common Stock |
2023-11-20 | Luo Ying | Buy | 2 262 755 | Stock Option (Right to Buy) |
2023-11-20 | Ye Weiguo | Buy | 1 665 115 | Stock Option (Right to Buy) |
2023-11-20 | Ma Songjiang | Buy | 4 510 047 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
21.61 |
Last 85 transactions |
Buy: 88 748 347 | Sell: 111 334 812 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.511 (-2.65% ) |
Volume | 0.461 mill |
Avg. Vol. | 0.437 mill |
% of Avg. Vol | 105.36 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Date | Signal | @ |
---|---|---|
SQQQ | Mar 28 - 14:57 | $10.41 |
FTNUSD | Mar 28 - 14:56 | 1.810 |
^NYA | Mar 28 - 14:42 | PTS18 301 |
^SPX | Mar 28 - 14:42 | 5 250.40 |
TUSDUSD | Mar 28 - 14:55 | $0.996 |
KP3RUSD | Mar 28 - 14:54 | 95.68 |
APE18876USD | Mar 28 - 14:54 | 2.01 |
ANKRETHUSD | Mar 28 - 14:55 | 4 068.09 |
BUSDUSD | Mar 28 - 14:55 | 0.995 |
BTCBUSD | Mar 28 - 14:55 | 70 529 |